Candel Therapeutics, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 28, 2024. This is an annual report, not a standalone fourth-quarter report. Candel is a clinical-stage biopharmaceutical company developing viral cancer immunotherapies; it has no approved products and has generated no product-sales revenue.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $0 | $0.125 million |
| Research and development expense | $24.506 million | $20.787 million |
| General and administrative expense | $13.885 million | $14.060 million |
| Total operating expenses / operating loss | $38.391 million | $34.847 million / $34.722 million loss |
| Net loss | $37.939 million | $18.794 million |
| Basic and diluted loss per share | $1.31 | $0.65 |
| Net cash used in operating activities | $34.244 million | $31.419 million |
Revenue in 2022 was the final recognition of prior research and development service revenue from a related-party license; that revenue was fully recognized by year-end 2022. Product margins are not meaningful because Candel has no product sales. The 2023 net loss increased despite lower general and administrative expense: R&D spending rose, interest expense increased, and the prior-year $16.370 million warrant-liability fair-value gain fell to $0.966 million in 2023. These warrant remeasurement gains are noncash and stock-price-sensitive.
At December 31, 2023, cash and cash equivalents were $35.413 million, down from $70.058 million; total assets were $41.201 million and stockholders’ equity was $12.745 million. Debt included a $20.0 million bank term loan (about $20.525 million net carrying amount) and a Periphagen note with a $0.751 million carrying value. The term loan bears a floating rate; its effective rate was 11.19% at year-end, with principal payments beginning February 2024 and maturity in January 2026. Management expects existing cash to fund its current operating plan into the fourth quarter of 2024, but states that substantial doubt exists about the company’s ability to continue as a going concern without additional funding. The audited statements assume continued operations and include no adjustments for this uncertainty.
Business, pipeline and material developments
- CAN-2409: Adenovirus-based candidate administered with valacyclovir. Its fully enrolled, 711-patient Phase 3 prostate cancer trial is expected to report topline data in Q4 2024; a 187-patient Phase 2 active-surveillance trial also has expected topline data in Q4 2024. FDA Special Protocol Assessment agreement does not guarantee approval.
- NSCLC: An open-label Phase 2 study combines CAN-2409 with continued checkpoint-inhibitor treatment. The company reported preliminary response and survival observations, including a 77% disease-control rate in a subset of Cohort 2 and 13% overall response rate across cohorts; overall survival was immature. Topline Cohort 2 survival data were anticipated in Q2 2024, assuming maturity. Recruitment was paused after target enrollment for Cohort 2.
- Pancreatic cancer: New enrollment in a randomized Phase 2 study was paused in March 2023, subject to additional funding. Preliminary results from a small treatment group (7 patients) showed estimated survival of 71.4% at 24 and 36 months versus 16.7% in the control arm; median overall survival was not reached in the treatment arm and was 12.5 months in control. These are interim findings, not definitive evidence. An update was expected in Q2 2024. FDA granted fast track designation in December 2023.
- CAN-3110: HSV-based candidate in an investigator-sponsored Phase 1b study for recurrent high-grade glioma. Reported median overall survival was 11.8 months in one arm and 12.0 months in a smaller second arm at an April 2023 cutoff; published analyses also associated HSV-1 antibody status and immune activation with survival. The study extension is testing repeat dosing, with additional data expected in the second half of 2024. FDA granted fast track designation in February 2024.
- Portfolio and costs: The company paused pancreatic enrollment for funding reasons and chose not to pursue a Phase 3 CAN-2409 glioma trial. In November 2023, it announced a restructuring focused on CAN-3110 and its enLIGHTEN discovery platform, reducing workforce by approximately 45%; it recorded $0.7 million in severance costs. It reported 42 employees at year-end.
- Other developments: Candel presented preclinical work on its enLIGHTEN platform and Alpha-201 Macro1. These remain investigational. The Periphagen license dispute was resolved by amendment in June 2023, with arbitration terminated and no financial impact reported.
Risks, contingencies and governance matters
- Going concern and financing: Candel expects continued losses, needs substantial additional capital, and has no committed external funding. Failure to raise funds could force delays, reductions or termination of trials and development programs. The company’s stated cash runway is into Q4 2024, not a guarantee of sufficient financing beyond that point.
- Significant quality and regulatory disclosure: In a March 15, 2024 letter, Candel notified former CEO and then-director Dr. Aguilar-Cordova of allegations that he instructed employees to falsify CAN-2409 sterility-test results submitted to the FDA and failed to implement an appropriate stability-testing program. Candel says it updated the stability program, submitted additional information to the FDA, and determined that patients were not placed at risk and clinical-data integrity was not affected. The former executive denied the allegations on March 26, 2024; Candel requested his immediate resignation from the board. The filing does not establish an adjudicated finding. This disclosure could have important regulatory, operational and governance implications.
- Clinical and regulatory risk: Candidates remain investigational; early, interim and small-cohort results may change and do not establish efficacy. Trials may fail, safety issues may emerge, and FDA fast track or SPA status does not assure faster review or approval.
- Operating and financing constraints: The company relies on third-party manufacturers and investigator-sponsored trials, has variable-rate debt and restrictive loan covenants, and may need to issue dilutive securities or license rights on unfavorable terms. It had only $0.2 million of net ATM proceeds through March 21, 2024.
- Other notable risks: Candel disclosed the former CFO’s resignation effective January 12, 2024 and appointment of an interim CFO. Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2023; the auditor did not attest to internal-control effectiveness because of the company’s emerging-growth-company exemption. The company also cited potential dilution from warrants and equity awards and acknowledged that it regained Nasdaq’s minimum bid-price compliance in December 2023 after receiving a deficiency notice.
Most important facts for investors to verify
- Progress of the FDA’s review of the sterility-testing and stability-program disclosures, any follow-up requirements, and the status of the former CEO/director allegations.
- Whether new financing is secured, the resulting dilution or debt burden, and whether funding supports the stated clinical plans beyond the Q4 2024 cash-runway estimate.
- Final, prespecified results and safety data for the CAN-2409 prostate, NSCLC and pancreatic studies, including whether endpoints and analyses support regulatory filings.
- Updated CAN-3110 survival and repeat-dose data, and whether the results are reproducible in appropriately controlled studies.
- Current debt-payment status, compliance with loan covenants, and cash and cash equivalents after year-end.
- Execution and consequences of the workforce reduction, including effects on trial operations, manufacturing readiness and regulatory oversight.